CBS 2019
CBSMD教育中心
English

动脉粥样硬化性心血管疾病预防

科研文章

荐读文献

International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials Coronary Atherosclerotic Precursors of Acute Coronary Syndromes Sox17 Controls Emergence and Remodeling of Nestin-Expressing Coronary Vessels Antithrombotic Management of Elderly Patients With Coronary Artery Disease Parallel Murine and Human Plaque Proteomics Reveals Pathways of Plaque Rupture Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk: Clinical Perspectives and Basic Implications Machine Learning Using CT-FFR Predicts Proximal Atherosclerotic Plaque Formation Associated With LAD Myocardial Bridging The Science Underlying COVID-19: Implications for the Cardiovascular System Cellular origin and developmental program of coronary angiogenesis

Review Article2021 Apr, 14 (7) 723–738

JOURNAL:JACC: Cardiovascular Interventions Article Link

Antithrombotic Management of Elderly Patients With Coronary Artery Disease

P Capranzano, DJ Angiolillo. Keywords: antithrombotic management; elderly; ischemic recurrence

ABSTRACT

Antithrombotic therapy represents the mainstay of treatment in patients with coronary artery disease (CAD), including elderly patients who are at increased risk for ischemic recurrences. However, the elderly population is also more vulnerable to bleeding complications. Numerous mechanisms, including abnormalities in the vasculature, thrombogenicity, comorbidities, and altered drug response, contribute to both increased thrombotic and bleeding risk. Age-related organ changes and drug-drug interactions secondary to polypharmacy lead to distinct pharmacokinetic and pharmacodynamic profiles of antithrombotic drugs. Overall these factors contribute to the risk-benefit profiles of antithrombotic therapies in elderly subjects and underscore the need for treatment regimens that can reduce bleeding while preserving efficacy. Given that the prevalence of CAD, as well as concomitant diseases with thromboembolic potential, such as atrial fibrillation, increases with age and that the elderly population is in continuous growth, understanding the safety and efficacy of different antithrombotic regimens is pivotal for patient-centered care. In the present overview the authors appraise the available data on the use of antithrombotic therapy in older patients with CAD to assist with the management of this high-risk population and define knowledge gaps that can set the basis for future research.